Current Report Filing (8-k)
March 26 2015 - 9:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
_______________________
Date of Report: March 26, 2015 (Date of
earliest event reported)
CAPSTONE THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-21214 |
|
86-0585310 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification
No.) |
|
|
|
|
|
1275 West Washington Street,
Suite 104, Tempe, Arizona |
|
85281 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code:
(602) 286-5520
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
[ ] Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 2—Financial Information
Item 2.02 Results of Operations and Financial Condition.
A copy of the presentation for the conference
call, referenced in the press release issued by Capstone Therapeutics Corp. on March 20, 2015, is furnished as Exhibit 99.1 to
this Current Report on Form 8-K, entitled “Capstone Therapeutics Corp. Operating Update, March 26, 2015”. The presentation
will also be accessible during the conference call by logging onto the Investors section of the Company’s website, www.capstonethx.com.
The information in Item 2.02 of this
Form 8-K and Exhibit 99.1 furnished herewith shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, regardless of any general incorporation language in any such filing.
Section 9 –
Financial Statements and Exhibits
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
Exhibit No. |
Description |
99.1 |
Capstone Therapeutics Corp. Operating Update, March 26, 2015 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: March 26, 2015 |
CAPSTONE THERAPEUTICS CORP. |
|
|
|
|
|
|
|
/s/ John M. Holliman, III |
|
John M. Holliman, III |
|
Executive Chairman |
Exhibit 99.1
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Jul 2023 to Jul 2024